<DOC>
	<DOCNO>NCT01999101</DOCNO>
	<brief_summary>The primary aim study evaluate safety tolerability Px-104 NAFLD patient assess influence Px-104 hepatic fat .</brief_summary>
	<brief_title>Safety Pilot Study Farnesoid X Receptor ( FXR ) Agonist Non-alcoholic Fatty Liver Disease ( NAFLD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>NAFLD patient Weight &gt; 65 kg BMI &gt; 25 &lt; 40 Negative blood urine pregnancy test ( female childbearing potential ) collect screen follow another negative serum pregnancy test collect within 24 hour prior first dose study drug . Contraception : Female patient must postmenopausal , surgically sterile , premenopausal , must prepare use least two effective ( ≤1 % failure rate ) method contraception course study 14 day end dose . Male patient female partner child bear potential must prepare use least two effective method contraception sexual partner unless prior vasectomy Must willing able give write informed consent agree comply study protocol . Sinus rhythm 12lead ECG Evidence excessive alcohol , drug substance abuse ( exclude marijuana use ) within 1 year first dose . History evidence medical condition associate chronic liver disease . History evidence decompensated liver disease ( ChildPugh Grade B high ) , coagulopathy , hyperbilirubinemia , hepatic encephalopathy , hypoalbuminemia , ascites , hepatic encephalopathy , bleed esophageal varix condition consistent decompensated liver disease . Concomitant intake fibrates statin ( least 46 week start ; consider half life medication ) . Any clinically relevant finding ECG ( identify via 24hHolter ECG 12Lead ECG ) screen History structural cardiac disease . In addition , patient document presumed unstable coronary artery disease , stable unstable cardiovascular disease cerebrovascular disease . One follow condition : ( 1 ) poorly control hypertension , OR ( 2 ) screen baseline blood pressure ≥ 160 mmHg systolic OR ( 3 ) screen baseline blood pressure ≥ 100 mmHg diastolic blood pressure . Type I II diabetes HbA1C &gt; 6.5 % screen and/or fast plasma glucose &gt; 7mmol/L ( &gt; 126 mg/dl ) . History evidence clinically relevant ophthalmologic disorder due diabetes mellitus hypertension history evidence severe retinopathy ( e.g. , cytomegalovirus , macular degeneration ) . Known sensibility ingredient contain investigational medicinal product ( IMP ) All condition allow magentic resonance ( MR ) assessments History receive investigational drug ≤ 3 month and/or 6 x halflife prior first dose study drug expectation drug use study . Patients enrol study enrol another study either research , diagnostic treatment purpose . Woman childbearing potential unless use adequate contraception ( see inclusion criterion ) ; female pregnant breast feeding . History severe allergic Evidence active suspect cancer , history malignancy within last 2 year , exception patient basal cell carcinoma excise cure . History systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) 6 month prior first dose study drug expectation treatment need time study . History bleed disorder anticoagulant use History evidence chronic pulmonary disease associate functional limitation . History uncontrolled severe seizure disorder . Poorly control thyroid dysfunction . History major organ transplantation exist functional graft . Any sign acute infection inflammation History evidence severe illness , condition would make patient , opinion investigator , unsuitable study . Any herbal supplement contain silymarin , tocopherol , vitamin C , riboflavins , proflavins , curcumin . ( least 46 month study ) Positive test screen antiHepatits A virus ( HAV ) Immunoglobulin M ( IgM ) , Hebatitis B surface antigen ( HBsAg ) , AntiHepatits B core Antigen Immunglobulin M antibody ( antiHBc IgM Ab ) , antiHIV Ab . Subjects undergone surgery within last 3 month . Subjects prior gastrointestinal surgery . Subjects unavailable duration trial , unlikely compliant protocol , felt b unsuitable investigator reason Imprisonment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>